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elen C. Routledge, MD, MRCP, Marie-Claude Morice, MD, FESC, FACC,
hierry Lefèvre, MD, FESC, FSCAI, Philippe Garot, MD, FESC,
ederico De Marco, MD, Beatriz Vaquerizo, MD, Yves Louvard, MD, FSCAI
assy, France
bjectives Our goal was to determine whether the deployment of drug-eluting stents (DES) in bi-
urcation lesions, according to a uniform provisional side-branch T-stenting strategy (PTS), is a safe
nd effective treatment in the immediate and long term.
ackground In comparison with simple stenoses, successful percutaneous intervention for coronary
ifurcation lesions is limited by a higher incidence of procedural complications and need for repeat
evascularization. The ideal strategy to overcome these limitations remains to be demonstrated
hile recent controversy surrounds the long-term safety of DES in bifurcations.
ethods Consecutive patients treated for bifurcation lesions using DES were studied in a prospec-
ive single-center registry. Between 2003 to 2005, 477 procedures were performed. The PTS strategy
as used in 92%, with a side-branch stent in 28% and ﬁnal kissing balloon inﬂation in 95%.
esults Angiographic success was achieved in 99% with 2.5% in-hospital major adverse cardiac
vents. The cumulative rate of major adverse cardiac events was 10.7% at 1 year and 13.6% at 2
ears, including 6.9% and 8.9% target vessel revascularization. Deviation from the PTS strategy inde-
endently predicted 2-year mortality (odds ratio: 5.5 [95% conﬁdence interval: 1.63 to 18.3], p 
.01). The rate of deﬁnite or probable stent thrombosis at 2 years was 2.5% with half of all events
ccurring before hospital discharge.
onclusions The PTS strategy for the treatment of bifurcation lesions is applicable to over 90% of
atients in the real world. With DES, both safety and efﬁcacy have been demonstrated in the long-
erm with 10% need for repeat revascularization in the ﬁrst 2 years and a low incidence of late
tent thrombosis. (J Am Coll Cardiol Intv 2008;1:358–65) © 2008 by the American College of
ardiology Foundation
rom the ICPS Institut Cardiovasculaire, Paris Sud, Massy, France.anuscript received April 4, 2008; accepted May 18, 2008.
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359hile rapid advances have been made in the percutaneous
reatment of obstructive coronary artery disease, progress in
he treatment of those 15% to 20% lesions that involve the
ifurcation between 2 branches has been limited by 3 main
roblems. Procedural success rates are lower, periprocedural
yocardial infarction (MI) is more common, and restenosis
ates and the need for repeat revascularization remain higher
han in the treatment of simple coronary lesions (1–3).
lthough success rates in the main vessel (MV) improved
ith the introduction of coronary stenting, the incidence of
See page 366
ide branch (SB) occlusion and restenosis remained high
4–7). With bare-metal stents (BMS), it became apparent
hat a stent deployed in the SB in fact offered no advantage
ver balloon angioplasty alone (5,7–9).
Encouragingly, revascularization rates seem to be reduced
y the use of drug-eluting stents (DES) in bifurcation
esions (10), although this remains an ‘off-label’ indication,
nd according to initial studies the problem of SB restenosis
ersists (11). Recent trial data suggest that with DES a
imple MV stenting strategy is at least equivalent in the
hort-term to more complex techniques (12). The longer-
erm efficacy of this strategy, however, still remains to be
emonstrated, as does its applicability to the wider group
Figure 1. Procedure for Treatment of Bifurcations Using a Provisional
T-Stenting Strategy
1. Wires are advanced in both the distal main vessel and 2. the side
branch; 3. The main vessel is pre-dilated if deemed necessary. Pre-dilation
of the side branch is avoided where possible; 4. A stent is deployed in the
main vessel, jailing the wire in the side branch; 5. Once the main vessel
result is seen to be satisfactory, wires are exchanged with the main vessel
wire being withdrawn and advanced through the stent struts into the side
branch; 6. A kissing inﬂation is systematically performed in order to open
the stent struts to cover the ostium of the side branch, while preserving
the result in the main vessel; 7a. If at this point there is normal (Thrombol-
ysis In Myocardial Infarction ﬂow grade 3) ﬂow in the side branch and
50% residual angiographic stenosis, this marks the end of the procedure;
7b. If this is not achieved, a second stent is deployed in the side branch.
The side branch stent crosses the struts of the ﬁrst stent and is deployed in
a T conﬁguration; followed by 7c. a ﬁnal kissing inﬂation to optimize 7d.d
the ﬁnal result in both branches.f patients, lesions, and stents in a nontrial setting.
hether DES are the solution for bifurcation lesions and
he optimal manner in which they should be deployed
hus both remain in question. Finally, the current con-
roversy concerning the risk of late DES thrombosis
aises further questions regarding the safest treatment for
atients with bifurcation coronary disease. At present,
he longer-term follow-up of a large cohort of ‘real-
orld’ patients necessary to address this question is
acking.
Our center employs a uniform provisional SB T-stenting
trategy (PTS) for treatment of bifurcation lesions, which
as developed in the BMS era and is described in Figure 1.
he main objective of this study was to determine whether
he deployment of DES in bifurcation lesions, according to
his strategy, could overcome the
imitations described and prove
safe and effective treatment
oth in the immediate and long
erm.
ethods
tudy population. Data were
rospectively collected in a reg-
stry of consecutive patients un-
ergoing percutaneous coronary
ntervention (PCI) for bifurca-
ion lesions between 2003 and
005. All patients in whom 1 or
ore DES was deployed in any
ifurcation lesion other than the
eft main were included. No pa-
ient was excluded on the basis
f clinical presentation.
rocedure. The uniform PTS
trategy (Fig. 1) begins with wir-
ng of both branches in all cases.
re-dilation of the MV is per-
ormed if needed, and a DES deployed in the MV.
uidewires are exchanged and kissing balloon inflation
erformed; a stent is then deployed in the SB for significant
esidual stenosis (50%) or if the flow is Thrombolysis In
yocardial Infarction (TIMI) flow grade 3, and this is
ollowed by a final kissing balloon inflation. Final decisions
egarding technical strategy in each case were made by a
onsensus of opinion among the interventional team. Either
irolimus-eluting (Cypher, Cordis Corp., Miami Lakes,
lorida) or paclitaxel-eluting (Taxus, Boston Scientific
orp., Natick, Massachusetts) stents were deployed at the
perators’ discretion or according to availability.
edication. Before elective intervention, patients were pre-
reated with clopidogrel, or, in the case of urgent proce-
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
CK  creatine kinase
DES  drug-eluting stent(s)
MACE  major adverse
cardiac events
MI  myocardial infarction
MV  main vessel
PCI  percutaneous
coronary intervention
PTS  provisional T-stenting
SB  side branch
STEMI  ST-segment
elevation myocardial
infarction
TLR  target lesion
revascularization
TVR  target vessel
revascularizationures, a loading dose of 300 mg was given before catheter-
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360zation. Intravenous aspirin 250 to 500 mg was given at the
tart of any angioplasty and intravenous unfractionated
eparin to achieve and maintain an activated clotting time
f 300 to 350 s. Aspirin 75 mg daily was continued
ndefinitely with clopidogrel (75 mg or 150 mg for patients
80 kg), for a minimum of 2 months after deployment of
Cypher and 6 months after a Taxus stent. Glycoprotein
Ib/IIIa inhibitors were used in fewer than 5% cases at the
iscretion of the operator.
ndications. Indications for intervention were divided into
cute ST-segment elevation myocardial infarction
STEMI), non-STEMI or unstable angina, post-MI, stable
ngina, and silent ischemia. Post-MI included all patients in
hom the bifurcation was a non-target lesion documented
uring primary PCI or a target lesion treated within a
onth of STEMI.
eﬁnitions. A bifurcation lesion was defined as any lesion
reated involving or adjacent to a SB 2 mm in diameter.
esions were classified as types 1 to 4 according to the
efèvre classification (13) and according to the internal
ngle between the MV and the SB (in the working view),
ith a Y-shaped lesion having an angle 70° and a
-shaped lesion 70°.
Final treatment strategy was divided in 4 categories: PTS
13), systematic T-stenting with the SB stented first (14),
ulotte (15), and simultaneous kissing stents (16). The crush
echnique was not used (11).
ollow-up, end points. A 12-lead electrocardiogram was
erformed 1 h post-procedure and repeated at least once
efore discharge. Creatine kinase (CK) was measured at 18
o 24 h post-procedure in all cases and repeated as appro-
riate if new symptoms occurred. The 6-, 12-, and 24-
onth clinical follow-up was obtained by clinic visit or
elephone interview. Control angiography was clinically
riven (in presence of symptoms and/or of stress-induced
schemia). Revascularization was performed in the presence
f a significant (50%) diameter luminal narrowing. Cu-
ulative end points were analyzed at hospital discharge, 6,
2, and 24 months. Details of all deaths were obtained by
onsulting both the clinical records and attending physician.
ajor adverse cardiac events (MACE) were defined as any
ardiac death, early reintervention, Q- or non–Q-wave MI
r target vessel revascularization (TVR). The definition of
eri- or post-procedural MI was based on a rise in CK to
wice the upper limit of normal. The 23 patients presenting
ith STEMI or non-STEMI and an elevated baseline CK
ere exempt from this part of the analysis. During follow-
p, a clinical syndrome accompanied by the same rise in
nzymes was used to define MI and, if new Q waves were
ocumented, Q-wave MI.
Target lesion revascularization (TLR) was defined as
eintervention, either percutaneous or surgical, for in-stent
r in-segment restenosis. TVR was any intervention to treat
r bypass a lesion in any part of the treated vessel or itsranches. Stent thrombosis was defined as definite, proba-
le, or possible and classified according to timing by the
cademic Research Consortium criteria (17).
tatistical analysis. Discrete variables are expressed as per-
entages, and comparisons between 2 groups were made
ith chi-square or Fisher exact test. Continuous variables
re described as mean  SD with intergroup comparisons
eing made with unpaired Student t test. A p value 0.05
as considered statistically significant. Patient and proce-
ural variables that appeared to be associated with the
ccurrence of adverse events during follow-up, with a p
alue 0.1 in univariate analysis, were entered into multi-
ariate models using binary logistic regression. In order to
urther decipher modifiable factors that might influence
utcome when treating all patients with bifurcation lesions,
rocedural variables alone were entered into a second
ultivariate analysis. All data were analyzed with the use of
PSS 14 software (SPSS Inc., Chicago, Illinois).
esults
n total, between January 2003 and December 2005, 477
onsecutive bifurcation procedures were undertaken using
ES.
aseline characteristics. The characteristics of the patients
re summarized in Table 1. Almost one-third were patients
ith diabetes, and over two-thirds had multivessel disease.
eft ventricular ejection fraction was 55% in 90% of
atients where assessed by left ventriculography (63% cases),
lthough this was less likely to be recorded in acute MI.
Table 1. Baseline Characteristics of Patients
Age, mean (SD/range) 64 [12/30–88]
Men, (%) 81
Risk factors, n (%)
Diabetes 153 (32)
Hypertension 243 (51)
Hypercholesterolemia 262 (55)
Current smoker 176 (37)
Previous CABG, n (%) 7 (1.5)
Indication for intervention, n (%)
Stable angina 213 (45)
NSTEMI and UA 158 (33)
STEMI 17 (3.6)
Post-MI 48 (10)
Silent ischemia 41 (8.6)
Number of diseased vessels, mean  SD 1.97 0.78
Multivessel disease, n (%) 311 (68)
LV ejection fraction (%), mean  SD 60 12
Ejection fraction 50%, n (%) 42 (9.2)
CABG  coronary artery bypass grafting; LV  left ventricular; MI  myocardial infarction;
NSTEMI non–ST-segment elevationmyocardial infarction; SD standard deviation; STEMIST- segment elevation myocardial infarction; UA unstable angina.
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361The lesions treated are described in Table 2. Two-thirds
ere located at the left anterior descending-diagonal bifur-
ation and the majority were type 1 (Medina 1,1,1). Over
6% lesions had 50% SB narrowing. In 5%, the lesion
reated was the result of BMS restenosis.
rocedural data. The details of procedures and angio-
raphic results are summarized in Table 3. A PTS strategy
as used for 92% of lesions, and a second stent was
eployed in the SB in 28% of cases. Final kissing balloon
ngioplasty was achieved in over 95% of all procedures.
either patient or lesion characteristics differed significantly
etween the eventual 1- and 2-stent groups other than a
ower proportion of posterior descending-posterolateral ar-
ery bifurcation lesions in the 2-stent group (3% vs. 10%, p
0.02).
n-hospital outcome. In-hospital and follow-up data are
ummarized in Table 4. Angiographic success, defined as
esidual MV stenosis 30% and SB stenosis 50% by
isual assessment and TIMI flow grade 3 in both branches,
as achieved in 98.5%. Recovery to hospital discharge was
ncomplicated in 97.5%. Five patients (1%) died
n-hospital.
One death was the result of rupture of the diagonal vessel
nd cardiac tamponade during the procedure. One patient,
ho initially presented in cardiogenic shock after an out-
f-hospital cardiac arrest, died of probable myocardial
upture on day 5 after an initial period of stability. One
atient suffered a small vertebral territory cerebral infarct
ost-procedure; although antiplatelet therapy was not inter-
upted, the patient subsequently died of progressive cardiac
ailure on day 8. In 2 cases, death followed reintervention
or subacute stent thrombosis at 6 and 7 days, respectively.
n total, 1.3% of procedures were followed by emergency
eintervention, and in all cases this was the result of acute (3
Table 2. Lesion Characteristics (n  477)
Lesion Location n (%)
LAD/diagonal 315 (66)
Circumﬂex/obtuse marginal 100 (21)
PDA/PLA 38 (8)
Other 24 (5)
Restenosis 25 (5.2)
Lesion type
Type 1 348 (73)
Type 2 23 (4.8)
Type 3 17 (3.6)
Type 4 41 (8.6)
Type 4a 24 (5.1)
Type 4b 24 (5.1)
Bifurcation angle
Y type (70°) 382 (80)
T type (70°) 95 (20)LAD left anterior descending; PDA posterior descending artery; PLA posterolateral artery.ases) or subacute (3 cases) thrombotic occlusion. In all but
he 2 described in the above text, reintervention was
uccessful and the patients were discharged without further
omplication. Two patients had CK rise without any asso-
iated symptoms or complication bringing the total in-
ospital MACE rate to 2.5%.
-year outcome. Complete follow-up data were available for
9% of all patients at 12 months. Results are summarized in
able 4. Total mortality was 3.4% including in-hospital
eaths. Five of the 9 additional cardiac deaths in year 1
ccurred in patients with symptoms of heart failure docu-
ented before the initial procedure, and 4 of these deaths
ere attributable to probable stent thrombosis. The rate of
eath was lower (1.9%) in patients with a stable clinical
Table 3. Procedural Data
n (%)
Radial approach 350 (73.1)
6-F guide 474 (99.0)
Stenting strategy
PTS 442 (92.3)
T-stenting, SB stent ﬁrst 32 (6.7)
Culotte stenting 3 (0.63)
Kissing stents 2 (0.42)
Stents deployed
Main branch 474 (99.0)
Side branch 138 (28.8)
Both branches 133 (27.8)
Final kissing inﬂation 457 (95.4)
Angiographic success
Both branches 472 (98.6)
Main branch 477 (99.6)
Side branch 474 (98.8)
Other coronary lesion(s) treated 251 (52.4)
PTS provisional T-stenting; SB side branch.
Table 4. Clinical Outcome in Patients After 477 PCI Procedures for
Bifurcation Lesions*
In-Hospital
6-Month
(Cumulative)
12-Month
(Cumulative)
24-Month
(Cumulative)
Urgent re-PCI, % 1.3 — — —
QWMI, % 0.2 0.2 0.2 0.8
NQWMI, % 0.6 0.6 0.8 1.0
TLR, % — 2.3 3.9 5.2
CABG, % 0 0.9 0.9 1.1
Total TVR, % — 4.8 6.9 8.9
Cardiac death, % (n) 1.1 (5) 1.9 (9) 3 (14) 3.7 (17)
Total death, % (n) 1.1 (5) 2.1 (10) 3.4 (16) 5.4 (25)
Total MACE, % 2.5 7.8 10.7 13.7
*Complete follow-up data are available for 99% (n 472) at 12 and 97% (n 460) at 24 months.
CABG  coronary artery bypass grafting; MACE  major adverse cardiac events; NQWMI 
non–Q-wavemyocardial infarction; PCIpercutaneous coronary intervention; QWMIQ-wavemyocardial infarction; TLR target lesion revascularization; TVR target vessel revascularization.
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362resentation. Two deaths occurred after repeat coronary
ntervention. There were no Q-wave MIs, but 1 non–Q-
ave MI in a patient who died. TLR was undertaken in 18
atients (3.9%) and revascularization in another segment of
of the 2 vessels involved in the bifurcation in a further 14
3.0%), so there was a total TVR of 6.9%. In 3 of these
ases, TVR was by bypass surgery. Overall cumulative
ACE at 12 months was 10.7%.
-year outcome. 2-year data were available in 97% of cases
nd are summarized in Table 4. Total mortality was 5.4%
total cardiac mortality 3.7%), with 3 additional cardiac
eaths occurring in the second year (2 sudden deaths and 1
eath after a Q-wave MI in a nontreated territory). Of those
urviving, 92% were entirely free of angina. In total, 8.9% of
atients had undergone TVR over the 2-year period, in-
luding 1 more patient undergoing bypass surgery in the
econd year. Freedom from MACE at 2 years was 86.3%
Fig. 2).
redictors of outcome at 2 years. The need for reinterven-
ion was not determined by any procedural variable, with no
ignificant relation to the use of 1 or 2 stents or to the type
f stent deployed. In multivariate analysis, the only predic-
ors of TVR were type 4b (Medina 0,0,1) bifurcations (odds
atio: 2.98 [95% confidence interval (CI): 1.04 to 8.55, p 
.05] and MV angiographic success, a negative predictor of
VR (odds ratio: 0.07 [95% CI: 0.05 to 0.11], p 0.0005).
The risk of death at 2 years was associated with advanced
ge, diabetes, multivessel disease, and an initial presentation
ith acute coronary syndrome (Table 5), but not with the
essel involved, the lesion type, or bifurcation angle. Con-
erning procedural factors, however, the non-use of a PTS
trategy was associated with mortality both in-hospital (60%
f all deaths vs. 7.2% of all survivors, p  0.005) and at 2
ears (28% vs. 6.4%, p  0.001) as was the deployment of
tents in both branches (44% vs. 26%, p  0.05). By
Figure 2. Kaplan-Meier Survival Curves Illustrating Outcome After
Bifurcation Intervention
Freedom from cardiac death (red line), freedom from death (black line),
freedom from death or target vessel revascularization (blue line), and
major adverse cardiac event-free survival (green line) at 2 years. Cum 
cumulative.ultivariate analysis (Table 6), the non-use of a PTS
trategy was the only independent predictor of death at 2
ears (odds ratio: 5.5 [95% CI: 1.6 to 18.3], p  0.01).
tent thrombosis. Cases of definite, probable, and possible
tent thrombosis are illustrated in Figure 3. At 2 years, the
ncidence of definite and probable stent thrombosis was
.5% with one-half of all these events occurring before
ospital discharge. The incidence of late stent thrombosis (2
robable cases) was 0.43%. There were no definite or
Table 5. Univariate Predictors of 2-Year Mortality*
No Death
(n  435)
Death
(n  25) p Value
Age (yrs) 63.6 11.6 72 11.0 0.0001
Diabetes 31% 52% 0.025
Dyslipidemia 55% 36% 0.06
Smoker 37% 16% 0.03
Stable angina 46% 24% 0.03
Unstable angina 32% 52% 0.04
Type 1 or 4 bifurcation lesion 80% 88% NS
T-shape angulation 19% 21% NS
Number of vessels diseased 1.94 0.78 2.40 0.82 0.004
EF (%) 60 12 50 18 0.07
Type 4 lesion 8% 20% 0.05
PTS approach 94% 72% 0.001
SB stent ﬁrst 5% 28% 0.001
Both branches stented 26% 44% 0.047
Stent length MV (mm) 20.5 7.0 23.6 7.7 0.03
Stent diameter MV (mm) 3.01 0.55 2.94 0.29 NS
Success both branches 99% 96% NS
Success MV 100% 96% 0.054
No stents outside bifurcation (n) 0.92 1.06 1.76 1.69 0.02
Other lesions treated (n) 0.75 0.89 1.36 1.22 0.001
Stent SB 27% 44% 0.07
SB Cypher 46% 27% NS
SB Taxus 24% 55% 0.04
SB BMS 30% 18% NS
SB stent length (mm) 13.4 5.1 17.6 4.7 0.01
SB stent diameter (mm) 2.58 0.27 2.57 0.23 NS
*Death occurred in 25 of 460 patients (5.4%).
BMS bare-metal stent; EF ejection fraction; MVmain vessel; other abbreviations as in
Table 3.
Table 6. Procedural Predictors of Death at 2 Years by Binary Logistic
Regression Analysis
OR 95% CI p Value
Nonuse of PTS strategy 5.46 1.63–18.3 0.006
SB not stented 0.90 0.31–2.57 NS
No stents outside bifurcation
(per extra stent)
1.51 1.11–2.07 NS
Type 4 lesion 2.78 0.90–8.53 NS
MV stent length (per mm) 1.51 0.99–1.11 NSCI confidence interval; OR odds ratio; MVmain vessel; other abbreviations as in Table 3.
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363robable cases of very late stent thrombosis but 4 unex-
lained or sudden deaths between 12 and 24 months, falling
nto the category of possible very late stent thrombosis.
espite small numbers, diabetes showed a significant asso-
iation, with 61% of all such events occurring in diabetic
atients (p  0.05 vs. nondiabetic patients).
iscussion
he main findings from this large, real-world registry are
hat the provisional SB T-stenting strategy described is a
afe and feasible technique, applicable to over 90% of all
ifurcation lesions encountered. Combining this technique
ith DES, we have demonstrated long-term efficacy in over
50 patients with a low rate of reintervention at 2 years.
rocedural success. The primary challenge in bifurcation
CI, to attain procedural success, remains an important
eterminant of outcome, but as illustrated here this can be
vercome in the vast majority of cases by using this PTS
trategy. The strategy was associated with an overall rate of
n-hospital adverse events of 2.5%. This compares favorably
ith historical data, where events after bifurcation treat-
ent have occurred at a rate of between 7% and 13% (3,8).
rate of post-procedural non–Q-wave MI of 0.5% in the
resent study suggests a very low incidence of SB loss. This
s unrelated to the use of DES (18) and instead supports the
echnical aspects of the procedure. We suggest that the
ystematic wiring of both branches (19) and the use of a
nal kissing inflation (20–22), irrespective of SB stenting,
re essential steps although the relative importance of each
annot be determined from this registry where both were
Figure 3. DES Thrombosis After Bifurcation Intervention
Incidences of stent thrombosis (ST) according to Academic Research Consortiu
tion lesions. CCF  congestive cardiac failure; LVF  left ventricular failure; MI
den cardiac death; TVR  target vessel revascularization; VF  ventricular ﬁbrised as default. meviation from PTS strategy. In keeping with data from our
MS registry (9), deviation from a PTS strategy was an
ndependent predictor of mortality. This finding, in the
resent study where all operators conformed where possible
o a uniform strategy, reflects lesion characteristics felt by
he team to be unfavorable for PTS. A systematic SB
tenting approach is more likely to be chosen in cases with
ong complex SB disease. Interestingly, as for BMS (9), type
lesions and longer SB stents were associated with a worse
utcome. Although SB lesion length was not included in
his analysis, intravascular ultrasound data suggest that
ignificant SB disease is a predictor of MACE (23). The
deal treatment strategy for this small proportion of patients
8%) with lesions deemed unsuitable for PTS revasculariza-
ion warrants further investigation.
ustained efﬁcacy of DES in bifurcations. The medium-term
fficacy of DES in PCI for bifurcation disease (10) has
lready been shown to be superior to that of BMS, where
-month event rates were as high as 27% to 50% (7,8). In
his study, the low rate of TVR at 6.9% (TLR 3.9%) by 1
ear is sustained at 8.9% at 2 years (TLR 5.2%). Whether
his improvement in longer-term efficacy is solely attribut-
ble to the DES or again reflects the stenting strategy
mployed necessitates a comparison with other techniques.
ccording to a registry of 241 bifurcations treated with
ES and a systematic 2-stent ‘crush’ technique, 9-month
LR was 9.7% (24), while in 205 patients treated for
ifurcation disease using PTS, TLR rates at 24  5 months
ere 8% (25). Interstudy comparisons of this nature are far
rom conclusive, but randomized studies comparing the
nitions, up to 2 years after drug-eluting stent (DES) deployment in bifurca-
ocardial infarction; PCI  percutaneous coronary intervention; SCD  sud-
.m deﬁ
 myany bifurcation techniques described are, so far, few in
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364umber. Two small studies (154 patients in total) have
uggested equivalent or lower revascularization rates with
irolimus-eluting stents comparing a provisional to a sys-
ematic SB stenting strategy (10,26). Subsequently, the
ulticenter Nordic study (12) randomized 207 patients
ith bifurcation lesions to a very simple (1 stent in the MB,
reatment of SB only in cases of TIMI flow grade 0 to 1)
nd 206 to a systematic 2-stent strategy. There were no
ignificant differences in TVR at 6 months; however, the
-stent strategy was associated with a higher rate of biomar-
ers of myocardial injury (18% vs. 8%, p 0.01). In contrast
o our data, these periprocedural non–Q-wave MI, which
ay represent SB occlusion, were not included in the
alculation of cumulative MACE, and their significance
ay not yet be apparent at 6-month follow-up (27,28). The
TS strategy used in our series lies between simple and
omplex with the aim of avoiding SB occlusion and obtain-
ng a good angiographic result in both branches using 1
tent only when possible. Notably, the use of an SB stent
tself in our series did not influence long-term TVR sug-
esting that the difference in revascularization rates between
and 2 DES in bifurcations, at least when T-stenting is
sed provisionally, may be less important than was the case
n the BMS era (7,9).
ong-term safety of DES in bifurcations. It is important to
etermine whether the reduction in need for revasculariza-
ion when using DES in bifurcations is offset by a reduction
n long-term safety. The results presented here do not
uggest that this is the case. Survival free of death or MI in
he present study at 12 months was 95.5% (92.7 at 2 years),
hile in our similar BMS registry concerning over 1,000
atients, the equivalent figure at 9 months was 94.5% (9).
The current predominant safety concern after PCI with
ES is the risk of stent thrombosis, and bifurcation
reatment has been shown to be a predictor of such events
29–31). Moreover, in the first study to demonstrate DES
fficacy in bifurcation lesions (10), the rate of definite and
robable stent thrombosis was 4.7% at 6-month follow-up,
ith all events occurring in patients treated with 2 stents
6.3% vs. 0%). A more recent study showed, using the
crush’ technique, a risk of stent thrombosis at 9 months of
.3% (15). In the present study, the rate of stent thrombosis
definite and probable) at 2 years was 2.5%, and half of all
hese events occurred before hospital discharge with each
atients undergoing immediate reintervention. The rate of
efinite, probable, and possible stent thrombosis of 3.6% is
ikely to be an overestimate as it assumes that all cardiac or
nexplained deaths in a population of patients with cardio-
ascular disease over 2 years are the result of stent throm-
osis. Here it is worth considering recent results of the
RTS II (Arterial Revascularization Therapies Study part
I) post-hoc analysis in which the treatment of bifurcation
esions with sirolimus-eluting stents, using 1 stent in theajority of cases, had no adverse influence on 1-year
utcomes of multivessel angioplasty (32).
tudy limitations. In this registry, although the need for
evascularization was low and over 90% patients were
symptomatic at 2 years, without systematic angiographic
ollow-up the rate of clinically silent SB restenosis may be
nderestimated. Comparisons with some historical data are
imited by the fact that a few studies have used troponin in
ome patients as a marker of periprocedural infarction (3).
his is a nonrandomized single-center study; thus, neither
an conclusions be drawn regarding differences between
tents nor can the reproducibility of the PTS technique in
ther centers guaranteed. A further limitation is that the
mportance of the final kissing inflation can only be hypoth-
sized. Some investigators have demonstrated that, at least
hen using suitably adapted devices, good results can be
btained from balloon dilation of the SB alone after MB
tenting (33). We remain limited to assumptions made from
ench testing models, which demonstrate that a kissing
nflation is required in PTS to ensure adequate stent
pposition proximal to and at the level of bifurcation (21).
inally, despite being a large series of bifurcation angio-
lasty, with the small number of deaths, the ability to
etermine univariate predictors of mortality remains
imited.
onclusions
sing this provisional SB T-stenting strategy for the treat-
ent of bifurcation lesions, the rate of angiographic success
s high and the procedure is safe with a low incidence of
eriprocedural MI and few early complications. This strat-
gy is applicable to over 90% nonselected lesions in the real
orld. Deployment of DES in bifurcations is effective in the
ong term, with a rate of reintervention in single figures up
o 2 years.
Although the risk of stent thrombosis remains higher in
ifurcations than in simple lesions, the additional risk of late
ES thrombosis is low with this approach, and this risk
oes not outweigh the benefit observed. A small subset of
atients with lesions unsuitable for PTS have worse
mmediate- and long-term outcomes, and further work is
equired to determine the optimal approach to their treatment.
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